Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $5.5
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Ricky Goldwasser has maintained an Equal-Weight rating on GoodRx Holdings (NASDAQ:GDRX) but reduced the price target from $8 to $5.5.
November 10, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on GoodRx Holdings but lowered the price target from $8 to $5.5, indicating a potential downside from the previous target.
The reduction in price target by a major analyst like Morgan Stanley suggests a bearish outlook on the stock's value, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100